Michael G. Hahn

Wuppertal, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial.

A novel TASK channel antagonist nasal spray reduces sleep apnea severity in physiological responders: a randomized, blinded, trial.

Journal: American journal of physiology. Heart and circulatory physiology
Published: January 12, 2024

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.

Journal: International journal of molecular sciences
Published: July 14, 2023

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

Journal: Respiratory research
Published: May 06, 2022

Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial.

Topical Potassium Channel Blockage Improves Pharyngeal Collapsibility: A Translational, Placebo-Controlled Trial.

Journal: Chest
Published: April 21, 2022

Soluble GC stimulators and activators: Past, present and future.

Soluble GC stimulators and activators: Past, present and future.

Journal: British journal of pharmacology
Published: August 23, 2021

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: August 09, 2021

Gain-of-function mutations in KCNK3 cause a developmental disorder with sleep apnea.

Gain-of-function mutations in KCNK3 cause a developmental disorder with sleep apnea.

Journal: Nature genetics
Published: August 05, 2021

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

Journal: Journal of medicinal chemistry
Published: April 19, 2021

Soluble guanylate cyclase stimulators and their potential use: a patent review.

Soluble guanylate cyclase stimulators and their potential use: a patent review.

Journal: Expert opinion on therapeutic patents
Published: January 04, 2021

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.

Journal: British journal of pharmacology
Published: November 26, 2020

Tyrosine 135 of the β1 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugs.

Tyrosine 135 of the β1 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugs.

Journal: European journal of pharmacology
Published: January 10, 2020

A lower X-gate in TASK channels traps inhibitors within the vestibule.

A lower X-gate in TASK channels traps inhibitors within the vestibule.

Journal: Nature
Published: July 08, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026